Novelix Pharmaceuticals Ltd (NOVELIX) Share Price & Fundamentals

What we do

Novelix Pharmaceuticals Limited operates in pharmaceutical manufacturing, research, and trading of bulk drugs and pharmaceutical intermediates, transitioning from investments to life sciences.

Founded in

1,994

Market share

Emerging player in pharmaceutical bulk drugs and healthcare analytics with expanding operations in eastern India.

Problem solved

Addresses the need for quality pharmaceutical bulk drugs and active pharmaceutical ingredients supporting healthcare and research sectors.

Top clients or who we serve

Serves pharmaceutical industries, healthcare research organizations, and retail pharmacy customers primarily in India.

Key management

Whole Time Director: Mr. Venkateshwarlu Pulluru; Independent Directors include Mr. Janardhan Das Kabra and Ms. Mayuri Baidya.

Our journey and innovations

Started as financial firm, diversified into pharma post 2006, ISO certified in 2009; rebranded in 2025; entered pharma manufacturing and healthcare analytics.

Where we operate

Operations primarily in India including Telangana, West Bengal, Assam, and Himachal Pradesh.

Top products or what we offer

Pharmaceutical bulk drugs, intermediates, active pharmaceutical ingredients, and healthcare research analytics services.

Top brands

-

Raw materials needed

Active pharmaceutical ingredients and intermediate chemicals for drug manufacturing.

Raw materials supplier

Procured from domestic chemical suppliers (specific names not disclosed).

Recurring vs cyclical contribution

Revenue is largely from cyclical pharmaceutical manufacturing and trading with emerging recurring research analytics services.

Our industry position

New entrant in pharmaceutical manufacturing with growing presence in eastern Indian markets and healthcare research segments.

Financial highlights

FY 2024-25 revenue Rs. 30.7 crore with PAT Rs. 8.45 lakh, showing growth from previous FY.

Geographical revenue split

Revenue mainly from Indian markets including Telangana, West Bengal, Assam, and Himachal Pradesh.

Order book

-

Whats driving growth

Shift into pharma manufacturing, new promoter-driven investments, and expansion into healthcare research and analytics.

Our future plans

Scaling pharmaceutical production, expanding healthcare research services, leveraging new promoter investments, and enhancing market reach.

Our green promise

-

Our people and values

Committed to ethical business practices with diverse board composition and employee engagement.

Key challenges ahead

Market competition, regulatory compliance, capital requirements, and scaling new pharma operations.

Interesting facts

ISO 9001 certified distributor since 2009; rebranded from Trimurthi Limited to Novelix Pharmaceuticals in 2025.

Risks and strategy

Mitigating market and operational risks through diversification, strong governance, and compliance adherence.